Notably, certain compounds, including imatinib, nilotinib, bafetinib, and radotinib, have demonstrated efficacy in preventing neurodegeneration in PD by inhibiting tyrosine phosphorylation and suppressing alpha-synuclein aggregation (Werner and Olanow 2022). Here, SNCA is linked to Parkinson disease.